Chronic obstructive pulmonary disease combines emphysema and chronic bronchitis, characterised by irreversible airflow obstruction and progressive lung-function decline. Smoking cessation is paramount. Inhalers, pulmonary rehabilitation, and oxygen therapy manage symptoms; stem-cell approaches are being researched to restore alveolar structure.
Short-acting beta-2 agonists (albuterol, terbutaline) provide acute bronchodilation; long-acting beta-2 agonists (salmeterol, formoterol) form the backbone of maintenance therapy. Inhaled corticosteroids (fluticasone, budesonide) reduce exacerbations, particularly in GOLD stage 3–4. Anticholinergics (tiotropium, ipratropium) add synergistic bronchodilation. Combination inhalers (ICS/LABA, LABA/LAMA) improve adherence and outcomes. Phosphodiesterase-4 inhibitors (roflumilast) reduce exacerbations in chronic-bronchitis phenotype. Pulmonary rehabilitation—exercise, breathing techniques, and nutritional support—improves exercise capacity and quality of life. Long-term oxygen therapy (LTOT) extends survival in hypoxaemic patients. Lung-volume-reduction surgery or endobronchial valves benefit select emphysema-predominant patients.
Smoking cessation—the single most important intervention—uses behavioural support, nicotine-replacement therapy, varenicline, or bupropion. Breathing exercises (pursed-lip breathing, diaphragmatic breathing) reduce dyspnoea. Herbal remedies (thyme, eucalyptus) are used symptomatically but do not alter disease progression. Acupuncture is explored for dyspnoea management with minimal evidence.
Stem-cell therapies are being studied for alveolar regeneration and emphysematous-defect repair. Mesenchymal stem cells may modulate lung inflammation and promote tissue remodelling. Placental-derived stem cells are under investigation for their anti-inflammatory properties. These approaches remain investigational and must accompany comprehensive COPD management. Consult candidacy criteria before trial consideration.
| Option | Type | الأدلة | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Long-acting beta-2 agonist (salmeterol, formoterol) | Standard | Strong | €400–700/year | Low | None |
| Inhaled corticosteroid (fluticasone, budesonide) | Standard | Strong | €300–600/year | Low | None |
| Long-acting muscarinic antagonist (tiotropium) | Standard | Strong | €350–650/year | Low | None |
| Pulmonary rehabilitation (exercise + education) | Standard | Strong | €1,500–3,000 (8–12 weeks) | Low | None |
| Long-term oxygen therapy (LTOT) | Standard | Strong | €2,000–4,000/year | Medium | None |
| Smoking cessation + breathing exercises | Alternative | Strong | €0–500 (cessation aids) | Low | None |
| Alveolar-regeneration stem-cell therapy | Regenerative | Investigational | €15,000–30,000 (trial-dependent) | Medium | 2–3 weeks |
Stem-cell therapy may slow emphysema progression and promote partial regeneration, but cure is not yet established. Early intervention is crucial; damage is irreversible once advanced.
No. Alpha-1 antitrypsin deficiency, occupational exposures (silica, asbestos), and air pollution cause COPD in non-smokers. However, smoking is the dominant risk factor.
GOLD stages (1–4) classify severity and guide therapy. FEV1 (forced expiratory volume in 1 second) is the primary measure: stage 1 (mild) >80%, stage 4 (very severe) <30% predicted.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية